Literature DB >> 10706226

Medical and surgical management of severe colitis.

J A Katz1.   

Abstract

The management of severe ulcerative colitis and Crohn's colitis remains a challenge, despite significant advances in medical and surgical therapy. Optimal management of the patient with severe colitis requires close collaboration between the gastroenterologist and surgeon. All patients with severe colitis should be hospitalized and treated with intravenous corticosteroids. If significant improvement does not occur within 7 to 10 days, then intravenous cyclosporine therapy or surgery is appropriate. Newer medical therapies, including heparin, tacrolimus, and other immunomodulatory agents, show promise for the treatment of severe colitis. When surgery is necessary, a total abdominal colectomy with ileostomy is the appropriate surgical intervention in most cases. In patients presenting with fulminant colitis, toxic megacolon, or perforation, earlier surgical intervention is indicated. The evaluation of and approach to the medical and surgical management of severe colitis will be reviewed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706226

Source DB:  PubMed          Journal:  Semin Gastrointest Dis        ISSN: 1049-5118


  10 in total

1.  A think tank of the Italian Society of Colorectal Surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: ulcerative colitis.

Authors:  F Selvaggi; G Pellino; G Ghezzi; D Corona; G Riegler; G G Delaini
Journal:  Tech Coloproctol       Date:  2015-09-19       Impact factor: 3.781

Review 2.  Surgery for inflammatory bowel disease.

Authors:  John M Hwang; Madhulika G Varma
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

3.  Derivation of a T2-weighted MRI total colonic inflammation score (TCIS) for assessment of patients with severe acute inflammatory colitis-a preliminary study.

Authors:  Rehana Hafeez; Shonit Punwani; Doug Pendse; Paul Boulos; Stuart Bloom; Steve Halligan; Stuart A Taylor
Journal:  Eur Radiol       Date:  2010-08-30       Impact factor: 5.315

4.  Surgical management of acute colitis and toxic megacolon.

Authors:  Tracey D Arnell
Journal:  Clin Colon Rectal Surg       Date:  2004-02

5.  Bolus injection of newly synthesized vitamin E derivative ETS-GS for the treatment of acute severe ulcerative colitis in a mouse model. New vitamin E derivative for acute severe UC.

Authors:  Takahiro Hiratsuka; Masafumi Inomata; Satoshi Hagiwara; Yohei Kono; Norio Shiraishi; Takayuki Noguchi; Seigo Kitano
Journal:  Int J Colorectal Dis       Date:  2012-07-31       Impact factor: 2.571

6.  Postoperative diagnostic revision for Crohn disease after subtotal colectomy for inflammatory bowel disease.

Authors:  Hélène Hermand; Jérémie H Lefèvre; Conor Shields; Najim Chafai; Clotilde Debove; Laurent Beaugerie; Magali Svrcek; Yann Parc
Journal:  Int J Colorectal Dis       Date:  2020-10-21       Impact factor: 2.571

Review 7.  Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis.

Authors:  Yuga Komaki; Fukiko Komaki; Akio Ido; Atsushi Sakuraba
Journal:  J Crohns Colitis       Date:  2015-12-08       Impact factor: 9.071

8.  Colectomy with ileostomy for severe ulcerative colitis-postoperative complications and risk factors.

Authors:  C Schineis; K S Lehmann; J C Lauscher; K Beyer; L Hartmann; G A Margonis; J Michel; C E Degro; F N Loch; F Speichinger; M E Kreis; C Kamphues
Journal:  Int J Colorectal Dis       Date:  2019-12-21       Impact factor: 2.571

9.  Outcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India.

Authors:  Sujoy Pal; Peush Sahni; Girish K Pande; Subrat K Acharya; Tushar K Chattopadhyay
Journal:  BMC Gastroenterol       Date:  2005-11-30       Impact factor: 3.067

10.  Primary ileo-anal pouch anastomosis in patients with acute ulcerative colitis.

Authors:  Jacek Hermann; Jacek Szmeja; Tomasz Kościński; Wiktor Meissner; Michał Drews
Journal:  Arch Med Sci       Date:  2013-02-10       Impact factor: 3.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.